
Big Pharma Uses Its Massive Profits to Enrich Shareholders, Not for Research
Big pharma justifies its exorbitant prices by arguing that the huge profits it nets from price markups will be spent on research. Yet the industry clearly prefers to funnel its profits to shareholders — which means enriching the already rich rather than spurring medical innovation.